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Abstract
Background: Dietary supplementation with tocotrienols has been shown to decrease the risk of coronary
artery disease. Tocotrienols are plant-derived forms of vitamin E, which have potent anti-inflammatory,
antioxidant, anticancer, hypocholesterolemic, and neuroprotective properties. Our objective in this study
was to determine the extent to which tocotrienols inhibit platelet aggregation and reduce coronary
thrombosis, a major risk factor for stroke in humans. The present study was carried out to determine the
comparative effects of a-tocopherol, a-tocotrienol, or tocotrienol rich fraction (TRF; a mixture of a-+g-+
δ-tocotrienols) on in vivo platelet thrombosis and ex vivo platelet aggregation (PA) after intravenous
injection in anesthetized dogs, by using a mechanically stenosed circumflex coronary artery model (Folts’
cyclic flow model).
Results: Collagen-induced platelet aggregation (PA) in platelet rich plasma (PRP) was decreased markedly after
treatment with a-tocotrienol (59%; P < 0.001) and TRF (92%; P < 0.001). a-Tocopherol treatment was less effective,
producing only a 22% (P < 0.05) decrease in PA. Adenosine diphosphate-induced (ADP) PA was also decreased
after treatment with a-tocotrienol (34%; P < 0.05) and TRF (42%; P < 0.025). These results also indicate that
intravenously administered tocotrienols were significantly better than tocopherols in inhibiting cyclic flow
reductions (CFRs), a measure of the acute platelet-mediated thrombus formation. Tocotrienols (TRF) given
intravenously (10 mg/kg), abolished CFRs after a mean of 68 min (range 22 -130 min), and this abolition of CFRs
was sustained throughout the monitoring period (50 - 160 min).
Next, pharmacokinetic studies were carried out and tocol levels in canine plasma and platelets were measured.
As expected, a-Tocopherol treatment increased levels of total tocopherols in post- vs pre-treatment specimens
(57 vs 18 μg/mL in plasma, and 42 vs 10 μg/mL in platelets). However, treatment with a-tocopherol resulted in
slightly decreased levels of tocotrienols in post- vs pre-treatment samples (1.4 vs 2.9 μg/mL in plasma and 2.3
vs 2.8 μg/mL in platelets). a-Tocotrienol treatment increased levels of both tocopherols and tocotrienols in
post- vs pre-treatment samples (tocopherols, 45 vs 10 μg/mL in plasma and 28 vs 5 μg/mL in platelets;
tocotrienols, 2.8 vs 0.9 μg/mL in plasma and 1.28 vs 1.02 μg/mL in platelets). Treatment with tocotrienols (TRF)
also increased levels of tocopherols and tocotrienols in post- vs pre-treatment samples (tocopherols, 68 vs 20
μg/mL in plasma and 31.4 vs 7.9 μg/mL in platelets; tocotrienols, 8.6 vs 1.7 μg/mL in plasma and 3.8 vs 3.9 μg/
mL in platelets).
Conclusions: The present results indicate that intravenously administered tocotrienols inhibited acute platelet-
mediated thrombus formation, and collagen and ADP-induced platelet aggregation. a-Tocotrienols treatment
induced increases in a-tocopherol levels of 4-fold and 6-fold in plasma and platelets, respectively. Interestingly,
tocotrienols (TRF) treatment induced a less pronounced increase in the levels of tocotrienols in plasma and
* Correspondence: qureshia@umkc.edu
1Department of Basic Medical Science, School of Medicine, 2411 Holmes
Street, University of Missouri, Kansas City. MO 64108, USA
Full list of author information is available at the end of the article
Qureshi et al. Lipids in Health and Disease 2011, 10:58
http://www.lipidworld.com/content/10/1/58
© 2011 Qureshi et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.platelets, suggesting that intravenously administered tocotrienols may be converted to tocopherols. Tocotrienols,
given intravenously, could potentially prevent pathological platelet thrombus formation and thus provide a
therapeutic benefit in conditions such as stroke and myocardial infarction.
Background
Americans are often encouraged to consume more fruits
and vegetables, and eat less red meat and dairy pro-
ducts, in order to lower total and LDL-cholesterol levels
and reduce the risk of developing atherosclerosis, plate-
let mediated coronary thrombosis, myocardial infarc-
tions, and strokes [1,2]. It is now known that oxidized
LDL-cholesterol is a much greater risk factor for the
development of atherosclerosis than its non-oxidized
precursor [3-7]. Dietary antioxidants, such as vitamin E
(a-tocopherol), have been shown to prevent LDL oxida-
tion and limit hypercholesterolemia in humans [8,9],
and it has been proposed that Vitamin E can prevent
vascular thrombosis and atherosclerosis [8-11]. A num-
ber of studies have suggested that dietary intake of small
doses of a-tocopherol reduces the risk of developing
coronary atherosclerosis [9,10], although this has not
been a universal finding [12,13].
The inhibitory effects of a-tocopherol on platelet func-
tion in vivo and ex vivo have been well established [14-18],
but inhibition of platelet aggregation by a-tocopherol
in vitro requires non-physiologically high levels of
a-tocopherol [14]. It is not surprising, therefore, that the
results of in vivo and in vitro studies are often in conflict
when studying the effects of a-tocopherol on platelet
aggregation [14-18]. The mechanism by which a-toco-
pherol reduces thrombosis and atherosclerosis is not well
defined [7,8], though a number of possible mechanisms
have been proposed; the antioxidant properties of
a-tocopherol are often implicated [8]. Recently, several
investigators have reported that tocotrienols (unsaturated
vitamin E) have 10- to 20-fold greater antioxidant activity
than a-tocopherol (vitamin E), and provide more efficient
protection against certain free radical-related diseases than
a-tocopherol [19-28].
The positive effects of tocotrienols (unsaturated vita-
min E; Figure 1) as anti-inflammatory, antioxidant,
anticancer (anti-proliferative), hypocholesterolemic, and
neuroprotective agents in animal and humans have been
confirmed by several investigators [23,29-39]. Tocotrie-
nols are naturally-occurring farnesylated unsaturated
analogs of a-, b-, g-a n dδ-tocopherols (Figure 1) iso-
lated from barley, rice bran, and annatto seeds [21]. The
Folts’ arterial injury model of stenosis and thrombosis
provides a system for evaluating the effects of various
natural products in vivo and ex vivo on platelet aggrega-
tion and thrombus formation [40]. In the experiments
described in this manuscript, we determined the effects
of a-tocopherol, a-tocotrienol, and a purified tocotrie-
nol rich fraction from palm oil without a-tocopherol
(TRF) on both in vivo platelet thrombus formation and
ex vivo platelet aggregation in the Folts’ model using
anesthetized dogs with mechanically stenosed circumflex
coronary arteries (MSCCA). The concentrations of toco-
pherols and tocotrienols were also estimated in pre-dose
and post-dose samples of plasma and platelets.
Materials and methods
Materials
Soluble equine tendon type I collagen and adenosine
diphosphate (ADP) were purchased from Chrono-Log
Corp (Havertown, PA, USA). Manual platelet counting
was performed using the Unipette System. Dogs were
obtained from the Medical School Facility of the Univer-
sity of Wisconsin, Madison, 53706, USA.
The investigation conforms with the guidelines for the
care and use of laboratory animals by the US National
Institute of Health (NIH publication 85-23, revised
1996), and the University of Wisconsin Research Animal
Resource Center. The protocol was reviewed and
approved by the University of Wisconsin-Madison Col-
lege of Agricultural and Life Sciences Animal Care and
Use Committee.
Canine model and surgical preparation
Ten dogs were anesthetized, the chest opened and the
heart exposed. The left circumflex coronary artery was
dissected out and an electromagnetic flow probe placed
circumferentially as previously described [40]. Distal to
the flow probe, the artery was clamped three times with
a special surgical clamp to produce intimal and medial
damage, and a plastic cylinder of appropriate diameter
was then placed circumferentially to produce a 70%
reduction in internal arterial diameter [40]. Platelet-
mediated thrombi periodically form at the site of
stenosis, and embolize distally. These thrombi were
monitored by the flow probe as cyclic flow reductions
(CFRs) in coronary blood flow (40). The size and
frequency of these CFRs is directly related to the level
of in vivo platelet activity [40]. The average body weight
of the dogs was 25 ± 0.6 kg for all groups.
Preparation of TRF (mixture of a-+g-+δ-tocotrienols)
free of a-tocopherol from palm oil by flash
chromatography
Silica gel (Merck, 230-400 mesh, 60 Å, 500 g) suspended
in 1000 mL of hexane was poured into a 1-L glass
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of hexane prior to being loaded with 100 g of tocotrie-
nol rich fraction from palm oil (containing 21% a-toco-
pherol) in 200 mL of hexane. The a-tocopherol was
removed selectively by washing with a mixture of 10%
ether in hexane (2 L), followed by washing with 30%
ether in hexane (2 L), and the eluted fraction was evapo-
rated under vacuum at 50°C, which yielded 66 g of toco-
trienol rich fraction (TRF) free from a-tocopherol. The
composition of various tocotrienols in this TRF was
determined by high pressure liquid chromatography
(HPLC) as described [41]. TRF was found to contain
a-tocotrienol (15%), g-tocotrienol (60%), and δ-tocotrie-
nol (25%). TRF was stored in polyethylene glycol at -20°
C at a concentration of 250 μg/mL. Plasma (40 mL)
was warmed to 50°C (20 min) prior to injection. The
a-Tocopherol (250 μg/mL), a-tocotrienol (250 μg/mL),
or TRF (a-+g-+δ-tocotrienols; 250 μg/mL) was dis-
solved in polyethylene glycol (1 mL of each) solution
and added to 40 mL of warmed plasma individually,
vortexed vigorously for 2 min, and then administered
over 30 seconds through a femoral arterial line as
Figure 1 Chemical structures of isomers of tocopherols and tocotrienols used in this study.
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present study is a mixture of a-, g-, and δ-tocotrienols,
free of a-tocopherol.
Ex vivo platelet aggregation
Canine platelet aggregation was performed using a
modification of a previously described human platelet
methodology [18,40]. Blood (30 mL) was drawn through
a femoral arterial line into 3.8% sodium citrate (1 citrate
to 9 parts blood). Platelet-rich plasma (PRP) was isolated
by centrifugation at 250 × g for 15 min. Platelet-rich
plasma was separated and platelet counting was per-
formed. The remaining blood was centrifuged further at
2,000 × g for 20 minutes and platelet-free plasma (PFP)
isolated. PRP platelet counts were adjusted with
corresponding PFP to equalize counts between pre- and
post-treatment specimens. PRP counts varied between
100,000 and 200,000 platelets/microliter. Platelet aggre-
gation was performed using a Sienco DP 247-E Dual
Sample Aggregometer (Morrison CO) and Omniscribe
recorder (Houston Instruments Model A5211-1), adjust-
ing PRP to 10% transmittance and PFP to 90%
transmittance.
Collagen (12.5 μmol/mL) or ADP (20 μmol/L), in
volumes of 32 μL were added to PRP (400 μL), after the
PRP was incubated at 37°C for 2 min. The extent of
collagen-induced platelet aggregation was quantitated by
measuring the percent aggregation 6 min after the addi-
tion of collagen. ADP-induced platelet aggregation was
quantitated by measuring percent aggregation at both
2.5 and 6.0 min after adding ADP.
Isolation and analyses of tocopherols and tocotrienols in
plasma and platelets by HPLC
Blood (30 mL) was drawn in EDTA (0.8 parts 77 μM
disodium EDTA to 9.2 parts blood) and PRP was pre-
pared from pre-dose and post-dose specimens as
described above. Platelets were separated from PRP by
centrifugation at 1950 × g for 20 min and the platelet
pellet washed twice with phosphate-buffered saline
(PBS). The final platelet pellet was suspended in 1 mL
PBS and platelets were counted. All samples were stored
at -20°C until assayed.
Estimations of tocols (mixture of a-, b-, g-, δ-toco-
pherol + a-, b-, g-, δ-tocotrienols) in plasma and platelet
fractions were carried out by HPLC using a modification
of a previously-described methodology [41]. Plasma (2
mL) or platelets (1 mL) were added to a 20 mL culture
tube, hexane (6 mL) was added, and these samples were
shaken in a horizontal shaker for 20 min, followed by
centrifugation at 1000 × g for 10 min. The hexane layer
(free tocols) was transferred to a 15-mL conical tube
and the solvent was removed under vacuum at 50°C in
a vortex evaporator. The remaining aqueous layer was
dried at 120°C in a vacuum oven (2 psi) for 60 min. The
residue was extracted with methanol (6 mL) using a
horizontal shaker for 30 min and centrifuged at 1000 ×
g for 15 min. The methanol soluble fraction (bound
tocols) was separated and concentrated under vacuum
at 50°C in a vortex evaporator. Tocols extracted by each
solvent were dissolved in hexane (0.5 mL), vortexed and
transferred to injecting vials (250 μL) the vials were
capped and centrifuged at 1000 × g for 5 min, followed
by HPLC analyses [41]. The tocols were eluted under
these conditions in sequence; a-tocopherol (5.2 min),
a-tocotrienol (5.6 min), b-tocopherol (6.8 min),
b-tocotrienol (7.2 min), g-tocopherol (7.8 min) g-tocotrie-
nol (8.1 min), δ-tocopherol (16.8 min) and δ-tocotrienol
(18.4 min), respectively. Values of the four separate iso-
mers of a-, b-, g-a n dδ-tocopherols and tocotrienols
were estimated separately, but combined values for the
four isomers of tocopherols or tocotrienols were
reported.
Statistical analyses
The data were analyzed by using the GLM procedure of
SAS (Statistical Analysis System) for personal computers
to test the Duncan’s multiple-range test to determine
whether the post-dose treated values differed from the
pre-dose values for a-tocopherol, a-tocotrienol, or TRF
treated groups. A two-way ANOVA was used to test
whether changes in collagen or ADP treated platelet
aggregation occurs during the treatments and whether
there were intra or inter- group differences between
tocol levels. The differences between means were also
evaluated using the paired, two-tailed student t-test
(StarView, Abacus Concept) and data were reported as
mean ± in the standard deviation. The level of statistical
significance was reported at 5% (P < 0.05).
Results
Effects of tocols on the levels of hematocrit and number
of platelets (counts) in whole blood and platelet rich
plasma (PRP)
In order to obtain an initial assessment of the effects of
treatment with various tocols on factors potentially
effecting thrombosis in dogs, we first measured the
effects of these treatments on hematocrit and platelet
counts. There were no significant differences between
pre-dose and post-dose hematocrit levels after treatment
with a-tocopherol (47.97 ± 6.36 vs 48.33 ± 0.64),
a-tocotrienol (49.47 ± 1.87 vs 46.40 ± 2.99), or TRF
(46.45 ± 5.84 vs 41.45 ± 7.01) as shown in Table 1. The
cumulative average pre-dose and post-dose platelet
counts in whole blood also did not change significantly
after treatment with a-tocopherol (234.83 ± 42.09 vs
188.33 ± 54.47), a-tocotrienol (262.67 ± 49.61 vs 188.00
± 36.23), or TRF (28.38 ± 63.25 vs 207.25 ± 43.25). In
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not change significantly with a-tocopherol (196.00 ±
6.93 vs 194.00 ± 6.00), a-tocotrienol (187.67 ± 10.79 vs
175.33 ± 10.79), and TRF (170.00 ± 24.49 vs 164.75 ±
17.42) thousand/μL (Table 1).
Effects of tocols in vivo
As mentioned above, none of these compounds, when
injected intravenously, had any significant effect on
hematocrit levels or platelet counts in whole blood or in
PRP, though small, non-significant decreases were
observed (Table 1), which is characteristic of this model.
We utilized the Folts’ arterial injury model of stenosis
and thrombosis because the effects of various
compounds on platelet aggregation and platelet-
mediated thrombus formation can be determined by
measuring the cyclic flow reductions (CRFs) in mechani-
cally stenosed circumflex coronary arteries (MSCCA).
The size and frequency of these CFRs is directly related
to the level of in vivo platelet aggregation activity
[42,43]. Specifically, platelet-mediated thrombi form
periodically in the stenosed coronary artery. This is fol-
lowed by distal embolization, which produces cyclic
reductions in measured coronary blood flow, known as
cyclic flow reductions (CFRs) [42,43]. It has also been
demonstrated that CFRs in mechanically stenosed
canine arteries can be eliminated by platelet inhibitors
(e.g. aspirin, prostacyclin, and the nitric oxide donor
sodium nitroprusside) [44,45].
In the present study, there were no significant changes
in blood pressure or heart rate during, or following, the
intravenous (IV) administration of a-tocopherol, a-toco-
trienol, or TRF. Importantly, however, the IV injection of
a-tocopherol, a-tocotrienol or TRF consistently
abolished cyclic flow reductions (CFRs) in mechanically
stenosed circumflex coronary arteries of dogs. The
average mean time between the IV injection of TRF (10
mg/kg) and the abolition of cyclic flow reduction (CFRs)
was 68.4 ± 12 min (range 22-130 min). Once abolished,
CFRs did not return to pre-dose values, despite challenge
with epinephrine (standard drug for restoring CFRs to
normal or pre-dose level) or increases in percent laminal
stenosis. Monitoring for the return of CFRs to pre-dose
l e v e l sw a sc o n t i n u e df o ra sl o n ga s1 6 0m i n( r a n g e5 0 -
160 min) post abolition of CFRs. Similar results were also
obtained with IV of a-tocopherol (20 mg/kg), and a-
tocotrienol (10 mg/kg) for CFRs. The average mean time
between a-tocopherol (20 mg/kg), a-tocotrienol (10 mg/
kg) or TRF (10 mg/kg; a-+g-+δ-tocotrienols) intrave-
nous administration and blood sample collection for
determining platelet aggregation and tocol levels was 88
± 10 min (41-117 min). The results of these studies sup-
port the concept that a-tocopherol, a-tocotrienol, and
TRF all have protective effects against intravenous plate-
let aggregation and thrombus formation.
Effects of a-tocopherol, a-tocotrienol or TRF on ex vivo
platelet aggregation
In order to further evaluate the potential protective
effects of tocols on platelet aggregation, we tested their
effect on ex vivo collagen-induced platelet aggregation
in PRP. Our results demonstrated that tocols had pro-
found, and significant, effects on collagen-induced plate-
let aggregation. Platelet aggregation in PRP 6 minutes
after treatment with a-tocopherol, a-tocotrienol, or TRF
(mixture of pure tocotrienols only) was reduced by 22%,
59% and 92%, respectively (P <0 . 0 0 1 ;F i g u r e2 ) .T R F
Table 1 Effects of tocols on hematocrit levels, and the
number of platelets in whole blood and in platelet rich
plasma in stenosed canine arteries
Hematocrit
1
Dogs Pre-dose Post-dose
a-Tocopherol 47.97% ± 6.36 (100)
4 48.33% ± 0.64 (101)
a-Tocotrienol 49.47% ± 1.87 (100) 46.40% ± 2.99 (94)
TRF
3 46.45% ± 5.84 (100) 41.45% ± 7.01 (89)
Platelet Counts in Whole Blood
2
Dogs Pre-dose Post-dose
a-Tocopherol 234.83 ± 42.09 (100)
4 188.33 ± 54.47 (80)
a-Tocotrienol 262.67 ± 49.61 (100) 188.00 ± 36.23 (72)
TRF
3 280.38 ± 63.25 (100) 207.25 ± 43.25 (74)
Platelet Counts in Platelet Rich Plasma
1
Dogs Pre-dose Post-dose
a-Tocopherol 196.00 ± 6.93 (100)
4 194.22 ± 6.00 (99)
a-Tocotrienol 187.67 ± 10.79 (100) 175.33 ± 10.79 (93)
TRF
3 170.00 ± 24.49 (100) 164.75 ± 17.42 (97)
1Average of 3 or 4 treatments: a-Tocopherol (1 + 2 + 3); a-Tocotrienol
(4 + 5 + 6); TRF (mixture of a-, g-, δ-tocotrienols; 7 + 8 + 9 + 10). Reported as
thousands/μl.
2Average of duplicate analyses of 3 or 4 treatments: a-Tocopherol (1 - 3);
a-Tocotrienol (4 - 6); TRF (7 - 10). Reported as thousands/μl.
3TRF = tocotrienol rich fraction (a-tocotrienol + g-tocotrienol + δ-tocotrienol)
4Percentages of pre-dose or post-dose values are in parentheses.
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Figure 2 Effects of a-tocopherol, a-tocotrienol, and tocotrienol rich fraction (TRF) on collagen-induced platelet aggregation: a-
Tocopherol (250 μg), a-tocotrienol (250 μg) or TRF (250 μg) were dissolved in polyethylene glycol (1 mL) solvent and stored at -20°C. Plasma
(40 mL) was warmed to 50°C (20 min) prior to injection. a-Tocopherol, a-tocotrienol or TRF solutions in 1 mL of polyethylene glycol were added
to warmed plasma, vortexed vigorously, and then administered over 30 seconds through a femoral arterial line to anesthetized dogs. Collagen
(12.5 μmol/mL) in a volume of 32 μL was added to 400 μL of PRP that had been incubated at 37°C for 2 min. The extent of collagen-induced
platelet aggregation was quantitated by measuring the percent maximal aggregation 6 min after adding collagen. Data are expressed as means
± SD, n =3( a-tocopherol), 3 (a-tocotrienol), and 4 (TRF) dogs respectively, per treatment. Figure 2A is based on raw values and 2B is based on
percentages compared to their respective pre-dose and post-dose control values. An asterisk indicates significant differences at P < 0.001 for
each treatment compared to respective controls.
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compounds.
Tocols (a-tocopherol, a-tocotrienol, or tocotrienols
[a-+g-+δ-tocotrienol]) also significantly inhibited ade-
nosine diphosphate (ADP)-induced platelet aggregation
in platelet rich plasma (PRP) as shown in Figure 3.
Compared to pre-dose values, the extent to which plate-
let aggregation was inhibited at 2.5 and 6.0 min after
the addition of ADP was 14% and 16% (P < 0.05) for a-
tocopherol, 24% and 34% (P < 0.05) for a-tocotrienol,
and 22% and 42% (P < 0.025) for TRF (Figure 3). The
maximal inhibition of platelet aggregation was, again,
obtained with TRF (Figure 3).
Effects of a-tocopherol, a-tocotrienol and TRF on the
concentrations of tocols in plasma and platelets of dog
The concentrations of a-, b, g, δ-tocopherols and a-, b-,
g-, δ-tocotrienols were estimated in plasma and platelets
before injection and after CFRs were abolished. Follow-
ing a-tocopherol treatment, tocopherol levels increased
from 17.60 ± 0.32 to 56.91 ± 0.18 μg/mL (P < 0.025) in
pre-dose vs post-dose plasma specimens, respectively,
and from 10.05 ± 0.27 to 42.22 ± 0.21 μg/mL in pre-
dose vs post-dose platelets, respectively (P < 0.025) as
s h o w ni nT a b l e2 .O nt h eo t h e rh a n d ,a-tocopherol
treatment did not significantly change tocotrienol levels
in plasma (2.89 to 1.49 μg/mL) or in platelets (2.84 to
2.33 μg/mL; Table 2). Following a-tocotrienol treatment,
tocopherol levels increased from 10.10 ± 0.82 to 45.11 ±
2.19 μg/mL in pre-dose vs post-dose plasma specimens,
respectively, and from 5.12 ± 1.24 to 28.16 ± 1.54 μg/
mL in pre-dose vs post-dose platelets (P < 0.025) as
s h o w ni nT a b l e3 .a-Tocotrienol treatment induced
relatively modest increases in tocotrienol levels in
plasma (0.90 ± 0.03 to 2.78 ± 0.13) and in platelets (1.02
± 0.03 to 1.28 ± 0.04) as shown in Table 3. Pre-dose vs.
post-dose levels of tocopherols and tocotrienols were
also increased significantly with TRF treatment (toco-
pherols in plasma, 19.72 ± 1.29 to 67.38 ± 2.25 μg/mL;
tocotrienols in plasma 1.65 ± 0.03 to 8.56 μg/mL ± 0.04;
tocopherols in platelets, 7.85 ± 0.62 to 31.44 ± 1.84;
tocotrienols in platelets, 3.85 ± 0.23 to 3.84 ± 0.12 μg/
mL) as shown in Table 4.
Although treatment with the various tocols had rela-
tively modest effects on pre-dose vs. post-dose treat-
ment levels of tocotrienols, these same treatments had
much more profound effects on tocopherol levels
(Tables 3, 4). After a-tocopherol treatment, total toco-
pherol concentrations increased approximately 3-fold in
plasma and 4-fold in platelets (Table 2). Similarly, after
treatment with a-tocotrienol and TRF, tocopherol levels
increased more than a 4-fold and 5-fold, in plasma and
platelets, respectively (Tables 3, 4). It has been demon-
strated that administering g-tocotrienol or TRF25
capsules to hypercholesterolemic humans for 4-weeks
significantly increased serum a-tocopherol concentra-
tions compared to baseline values [33,41]. This biocon-
version was further confirmed by demonstrating the
conversion of g-(4-
3H) tocotrienol to a-tocopherol in
vivo using chickens [35,37,41].
Discussion
Results of the present study clearly demonstrate the
inhibitory effect of tocotrienols on in vivo platelet
thrombus formation and ex vivo platelet aggregation
using the Folt’s stenosed canine coronary artery model.
Significant and marked inhibition of collagen- or ADP-
induced platelet aggregation was observed with a-toco-
trienol and TRF (a-, + g-, + δ-tocotrienols) treatments.
This inhibition exceeded that achieved with a-toco-
pherol under similar conditions (Figs. 2, 3). This is the
first report in which the effects of tocotrienols on plate-
let aggregation in vivo and ex vivo have been evaluated
using the Folts’ Model [40]. Although a-tocopherol, a-
tocotrienol and TRF treatments were all effective in
inhibiting collagen- and ADP-induced platelet aggrega-
tion in platelet rich plasma, the inhibition achieved with
TRF was significantly greater than that observed with
either a-tocopherol or a-tocotrienol. As mentioned ear-
lier, the TRF used in this study contained a-, g-a n dδ-
tocotrienols (15%, 25%, and 60%, respectively), and was
free of a-tocopherol.
Treatment with all of the tocols produced significant
and pronounced increases in tocopherol concentrations
in plasma and platelets. The effect of tocol treatments
on tocotrienol levels was much more modest. It is
important to recognize that a-tocopherol is the major
form of vitamin E in plasma and platelets, even after
treatment with pure a-tocotrienol or TRF25, due to bio-
conversion of tocotrienols to a-tocopherol [33-39,41].
The conversion of tocotrienols to a-tocopherol in
plasma or platelets following IV injection in the current
s t u d ys u g g e s t st h a tu p t a k eo ft o c o t r i e n o l sb yp l a s m ao r
platelets is relatively rapid in the Folts model. To our
knowledge, the time dependency of tocotrienol uptake
in plasma or platelets has not been reported, and the
results reported herein suggest that the majority of toco-
trienols are ultimately converted to tocopherols as
reported earlier [35,37,41], although the site of this con-
version cannot be determined from the present data.
Moreover, it is also unclear if the biological effects
d e s c r i b e da b o v e( i . e .d e c r e a s e dp l a t e l e ta g g r e g a t i o n ,
abrogation of CRF’s) are secondary to tocotrienols, toco-
pherols, or a combination of both. The magnitude of
the increase in plasma or platelet tocopherol concentra-
tions in the present study is greater than that achieved
in most dietary supplementation studies using a-toco-
pherol or tocotrienols, and it could be speculated that
Qureshi et al. Lipids in Health and Disease 2011, 10:58
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Figure 3 Effects of a-tocopherol, a-tocotrienol, and tocotrienol rich fraction (TRF) on adenosine diphosphate-induced platelet
aggregation: a-Tocopherol (250 μg), a-tocotrienol (250 μg) or TRF (250 μg) were dissolved in polyethylene glycol (1 mL each) and stored at
-20°C. Plasma (40 mL) was warmed to 50°C (20 min) prior to injection. The a-tocopherol, a-tocotrienol or TRF solution was added to the
warmed plasma and vortexed vigorously, and then administered over 30 seconds through a femoral arterial line of the anesthetized dog.
Adenosine diphosphate (ADP; 20 μmol/mL) in a volume of 32 μL was added to 400 μL of PRP that had been incubated at 37°C for 2 min. The
extent of adenosine diphosphate -induced platelet aggregation was quantitated by measuring the percent maximal aggregation at 2.5 min and
6 min after adding ADP. Data are expressed as means ± SD, n =3( a-tocopherol), 3 (a-tocotrienol), and 4 (TRF) dogs respectively, per treatment.
Figure 3A is based on raw values and 3B based on percentages compared to their respective pre-dose and post-dose control values. An asterisk
indicates significant differences at P < 0.05 for each treatment compared to their respective control values.
Qureshi et al. Lipids in Health and Disease 2011, 10:58
http://www.lipidworld.com/content/10/1/58
Page 8 of 13tocotrienols are utilized more efficiently than tocopher-
ols by plasma or platelets. The increase in plasma toco-
pherols was also greater than that seen in most dietary
supplementation studies using various formulations of
a-tocopherol in TRF25 or Palmvitee capsules [35,37,41].
Whether the greater plasma and platelets levels of
tocopherols in the present study are the result of a
unique effect of tocotrienols, the intravenous route of
administration, the formulation used (TRF25, Palmvitee),
or an effect of improved recovery during assay of these
vitamin E compounds, cannot be determined from these
data.
Table 3 Effects of a-tocotrienol on the concentration of tocols in canine plasma and platelets
1
Treatments Total tocopherols (T)
2 Total tocotrienols (T3)
3 Total T + T3
a-Tocotrienol (T3) Concentrations in μg/ml (ppm)
Plasma (Pre-dose)
Total Tocols
4 10.10 ± 0.82
a (92)
5 0.90 ± 0.03
a (8) 11.02 ± 0.81
a (100)
Plasma (Post-dose)
Total Tocols 45.11 ± 2.19
b (94) 2.78 ± 0.13
b (6) 47.89 ± 2.17
b (100)
Platelets (Pre-dose)
Total Tocols 5.12 ± 1.24
a (83) 1.02 ± 0.03
a (7) 6.14 ± 1.22
a (100)
Platelets (Post-dose)
Total Tocols 28.16 ± 1.54
b (96) 1.28 ± 0.04
a (4) 29.44 ± 1.52
b (100)
1Data expressed as means ± SD, n = 3, 3, and 4 respectively, per treatment.
2Total tocopherols = Mixture of a-tocopherol + b-tocopherol + g-tocopherol + δ-tocopherol (T).
3Total tocotrienols = Mixture of a-tocotrienol + b-tocotrienol + g-tocotrienol + δ-tocotrienol (T3).
4Tocols = Mixture of a-, b-, g-, and δ-tocopherols (T) + a-, b-, g-, and δ-tocotrienols (T3).
5Percentages of control values are in parentheses.
a-bValues in columns with a different superscript letter are significantly different at P < 0.05.
Table 2 Effects of a-tocopherol on the concentration of tocols in canine plasma and platelets
1
Treatments Total tocopherols (T)
2 Total tocotrienols (T3)
3 Total T + T3
a-Tocopherol (T) Concentrations in μg/ml (ppm)
Plasma (Pre-dose)
Total Tocols
4 17.60 ± 0.32
a (86)
5 2.89 ± 0.05
a (14) 20.49 ± 0.26
a (100)
Plasma (Post-dose)
Total Tocols 56.91 ± 0.18
b (97) 1.49 ± 0.03
b (3) 58.40 ± 1.65
b (100)
Platelets (Pre-dose)
Total Tocols 10.05 ± 0.27
a (80) 2.84 ± 0.02
a (20) 12.89 ± 0.29
a (100)
Platelets (Post-dose)
Total Tocols 42.22 ± 0.21
b (95) 2.33 ± 0.04
a (5) 44.55 ± 0.22
b (100)
1Data expressed as means ± SD, n = 3, 3, and 4 respectively, per treatment.
2Total tocopherols = Mixture of a-tocopherol + b-tocopherol + g-tocopherol + δ-tocopherol (T).
3Total tocotrienols = Mixture of a-tocotrienol + b-tocotrienol + g-tocotrienol + δ-tocotrienol (T3).
4Tocols = Mixture of a-, b-, g-, and δ-tocopherols (T) + a-, b-, g-, and δ-tocotrienols (T3).
5Percentages of control values are in parentheses.
a-bValues in columns with a different superscript letter are significantly different at P < 0.05.
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Page 9 of 13Although, the present study does not delineate the
mechanism of action of tocopherols or tocotrienols on
platelet function, previous reports have suggested that
a-tocopherol inhibits platelet thromboxane A2 produc-
tion, increases vascular PGI2 production, inhibits the
platelet release reaction, inhibits platelet calcium mobili-
zation, alters platelet membrane fluidity, and inhibits
platelet phospholipase A2 [46,47]. It has been also
demonstrated that tocotrienols are highly effective at
reducing expression of adhesion molecules on endothe-
lial cells and inhibiting monocyte adhesion to endothe-
lial cells [48].
Recently, it was reported that a-tocopherol inhibits
platelet-mononuclear cell interaction, platelet aggrega-
tion and platelet protein kinase activity induced with
either phorbol 12-myristate 13-actate or thrombin in
humans [49]. Dietary supplementation of a-Tocopherol
significantly inhibited the superoxide production, lipid
oxidation, IL-1b secretion monocyte-endothelial cell due
to inhibition of protein kinase activity [50]. In humans,
a-Tocopherol also partially inhibits platelet protein
kinase C (PKC), and this action of a-tocopherol on pla-
telet function provides new insights into the anti-throm-
botic and atherogenic properties of a-tocopherol [51].
Moreover, the mixture of a-, g-, δ-tocopherols were
more effective in preventing platelet aggregation as
compared to a-tocopherol alone observed in humans
[52]. This inhibition of platelet aggregation was
associated with increased release of nitric oxide due to
activation of endothelial constitutive nitric-oxide
synthase and protein kinase C [52]. Similarly, the effects
of a-tocopherol and g-tocopherol differ with respect to
low-density-lipoprotein oxidation, superoxide activity,
platelet aggregation and arterial thrombogenesis in
human studies [53]. g-Tocopherol is more potent than
a-tocopherol in these effects also [53]. However, most
studies only show an effect in cultured cells or under ex
vivo conditions. Importantly, cell culture studies are
often conducted under conditions of vitamin E
deficiency. This might partially explain the inconsistency
observed between cell culture studies and studies
performed in animals or humans [53].
Combined treatment of diabetic rats with a-tocopherol
and acetylsalicyclic acid (aspirin) had a greater inhibitory
effect on platelet aggregation, and reduced nitric oxide
production, than either treatment alone [47,54]. Combi-
nation therapy also improved balance of thromboxane
and prostacyclin compared to untreated diabetic rats
[47,54]. Consequently, this combination therapy appears
to induce beneficial physiologic changes that may protect
tissues from detrimental thrombotic and ischemic phe-
nomena [54]. It has previously been demonstrated that
Table 4 Effects of TRF on the concentrations of tocols in canine plasma and platelets
1
Treatments Total tocopherols (T)
2 Total tocotrienols (T3)
3 Total T + T3
TRF
4 Concentrations in μg/mL (ppm)
Plasma (Pre-dose)
Total Tocols
5 19.72 ± 1.29
a (92)
6 1.65 ± 0.03
a (8) 21.37 ± 1.13
a (100)
6
Plasma (Post-dose)
Total Tocols 67.38 ± 2.25
b (89) 8.56 ± 0.04
b (11) 75.94 ± 2.21
b (100)
Platelets (Pre-dose)
Total Tocols 7.85 ± 0.62
a (67) 3.85 ± 0.23
a (33) 11.70 ± 0.48
a (100)
Platelets (Post-dose)
Total Tocols 31.44 ± 1.84
b (89) 3.84 ± 0.12
a (11) 35.28 ± 1.70
b (100)
1Data expressed as means ± SD, n = 3, 3, and 4 respectively, per treatment.
2Total tocopherols = Mixture of a-tocopherol + b-tocopherol + g-tocopherol + δ-tocopherol.
3Total tocotrienols = Mixture of a-tocotrienol + b-tocotrienol + g-tocotrienol + δ-tocotrienol
4TRF = Tocotrienol Rich Fraction (Mixture of 15% a-tocotrienol + 60% g-tocotrienol + 25% δ-tocotrienol)
from palm oil (Purified at AMR, Madison, WI).
5Tocols = Mixture of a-, b-, g-, and δ-tocopherols (T) + a-, b-, g-, and δ-tocotrienols (T3).
6Percentages of control values are in parentheses.
a-bValues in columns with a different superscript letter are significantly different at P < 0.05.
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Page 10 of 13tocopherol levels in platelets are depressed in diabetic
subjects and that these low levels may contribute to the
increased incidence of atherosclerosis and thrombotic
events in diabetic patients [55-57]. Supporting this con-
cept is the demonstration that dietary a-tocopherol has
been demonstrated to reverse abnormalities of platelet
function in diabetic rats and patients [49-52]. The above
mentioned properties and other positive biological effects
of tocopherols have been reviewed comprehensive by
Reiter et al. [58].
Recently, tocotrienols were found to be potent neuro-
protective agents against stroke [31,59]. Specifically,
incorporation of tocotrienols into the diet of hyperten-
sive rats protected them against stroke-induced injury
[31,59]. This protective property of tocotrienols was due
its inhibition of pp66 (c-Src gene) kinase activation and
12-Lipoxygenase, which protect against glutamase- and
stroke-induced neurodegeneration [60]. This protective
effect of tocotrienols (in nanomolar concentrations) is
independent of their antioxidant activity because toco-
pherols were effective only at higher (micromolar) con-
centrations [32]. Recently, it was reported that g-
tocotrienol was the most cardioprotective of all the iso-
mers, followed by a- and δ-tocotrienols [61]. It was also
suggested that, although these isomers possess compar-
able antioxidant properties, their abilities to potentiate
signal transduction could be different [61]. On the other
hand, our previous and recent findings showed that
tocotrienols exhibit varying degrees of biological activity
with δ-tocotrienol showing the most potency, followed
by g-tocotrienol, and then by a-tocotrienol [23,29]. The
present results show that a mixture of tocotrienols con-
taining mainly g-, and δ-tocotrienol, is more potent than
a-tocotrienol with respect to inhibition of collagen- or
ADP-induced platelet aggregation. Further studies are
required to clarify the potency of g-tocotrienol vs δ-
tocotrienol.
Conclusions
Administration of intravenous tocotrienols markedly
inhibits collagen and ADP-induced platelet aggregation,
inhibits in vivo platelet thrombosis, and induces a 2-fold
and 4-fold increase in plasma and platelet levels of a-
tocopherol, respectively. These treatments induced less
pronounced increases in plasma or platelet tocotrienols
levels, suggesting that intravenous administered tocotrie-
nols were ultimately converted to tocopherols in this
model, comparable to results obtained in humans, ham-
sters, guinea pigs and swine [33-39,62-64]. The above
results also suggest that tocotrienols and tocopherols
may be important physiologically and therapeutically in
the prevention of thrombotic events and atherosclerosis,
and that tocotrienols can be used to supplement cur-
rently used antiplatelet agents. Aspirin and clopidogrel
resistance are well-described phenomena [65,66], and
the search for more effective anti-platelet agents is
ongoing. The enhanced cholesterol-lowering properties
of tocotrienols may make these compounds even more
attractive than a-tocopherol as potential therapeutic or
prophylactic agents for platelet inhibition and protection
against myocardial infarction and stroke.
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